News & Updates
Filter by Specialty:

Triplet therapy with ARSI, docetaxel, ADT boosts survival in mHSPC
05 Sep 2022
byTristan Manalac
Adding androgen receptor signaling inhibitors (ARSI) to a treatment regimen consisting of docetaxel and androgen deprivation therapy (ADT) can lead to better survival outcomes in patients with metastatic hormone-sensitive prostate cancer (mHSPC), according to a recent meta-analysis.
Triplet therapy with ARSI, docetaxel, ADT boosts survival in mHSPC
05 Sep 2022
Pandemic-fueled psych problems, fear of recurrence common among cancer patients
02 Sep 2022
Psychological problems, such as post-traumatic stress disorder (PTSD), depression, and anxiety, are common among cancer patients during the COVID-19 pandemic, as were fears of disease progression or recurrence, a recent study has found.